[Skip to Content]
[Skip to Content Landing]
Views 932
Citations 0
Research Letter
June 18, 2020

Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma

Author Affiliations
  • 1Scott Department of Urology, Baylor College of Medicine, Houston, Texas
  • 2Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio
  • 3James Buchanan Brady Urological Institutions, The Johns Hopkins Medical Institutions, Baltimore, Maryland
  • 4Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland
JAMA Oncol. Published online June 18, 2020. doi:10.1001/jamaoncol.2020.1641

The emergence of immune checkpoint inhibitors (ICIs) has provided previously unachievable curative therapy for many patients, particularly those with metastatic melanoma.1 However, the long-term outcomes for patients using ICIs are only beginning to be investigated. One important potential unexplored adverse effect is impaired male fertility. The current American Society of Clinical Oncology guidelines (July 2018) state that “sperm cryopreservation is effective, and health care providers should discuss sperm banking with postpubertal males receiving cancer treatment.”2(p1995) The direct association of ICI treatment with spermatogenesis has not been explored, to our knowledge.3 It will be critical to determine the risk to future male fertility for patients undergoing ICI therapy to accurately guide pretreatment counseling. To address the association between the potential gonadotoxic effect of ICIs and spermatogenesis, to our knowledge, we performed the first retrospective review of an index patient who became infertile after ICI therapy and subsequently died, and we performed a retrospective cohort cadaver study of patients with metastatic melanoma.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words